NEWS!Long time in waiting..... but finally have the patents!
Now its time to hit the road and drum up a sale!!!
RETLAW
VANCOUVER, BRITISH COLUMBIA, Mar 02 (Marketwire) --
Advanced Proteome Therapeutics Corporation (TSX VENTURE: APC) (the
"Corporation" or "APC") is pleased to announce that the European Patent
Office (EPO) intends to grant a patent directed toward a "Method for
identifying activated polymer complexes for secondary site-specific
modification of protein target groups" (European Patent Application No:
04 702 918.6). The patent has been assigned to its subsidiary, Advanced
Proteome Therapeutics Inc., by the inventor, Alexander Krantz, Ph.D.
The subject of the patent is a method for site-specifically modifying
proteins. Site-specific modifications are usually necessary to prepare
proteins for commercial use. The new patent describes a method for
discovering novel protein sites for attaching entities which are likely
to enhance the properties of proteins. The method consists of ensembles
of specially designed molecules that are in competition to selectively
modify protein molecules. The winning molecules are detected by their
greater abundance at specific target sites.
Potential applications include the creation of entirely new classes of
therapeutic proteins as well as new, improved versions of off-patent
proteins that have achieved multi-billion dollar sales per annum. Over
the past decade protein therapeutics has been the most dynamic sector of
the pharmaceutical industry. The global protein therapeutics market
registered a robust growth rate of over 14% in 2008.
The Corporation will also be presenting at BioTrinity 2010 in Newbury,
Berkshire, England on April 14th. Alexander Krantz, President and CEO
will present a profile of the Corporation reviewing its business
strategy, technological advantages and recent progress.
BioTrinity 2010 is the Premier Biopartnering and Investment Conference in
the UK and is Europe's fastest growing partnering conference with more
investors than any other UK conference (BioTrinity 2010 is also a
Massachusetts Biotechnology Council).
About APC
APC's primary corporate primary mission is to apply its proprietary drug
delivery and drug redevelopment technologies to produce new, improved
versions of therapeutic proteins and pioneer the emerging field of
protein-site targeting. The market for diagnostics and therapeutic
proteins and peptides is expected to surpass more than 50 Billion USD by
the year 2010 and is the fastest growing segment of the pharmaceutical
market. Future growth however depends largely on the industry overcoming
a number of hurdles, including drug delivery challenges and the need for
homogeneous conjugates that APC is attempting to address.